- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03422640
Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia
Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Clive M Liu, MD
- Phone Number: 425-455-2275
- Email: Cliveliumd@gmail.com
Study Contact Backup
- Name: Ivy T Chan, BA
- Phone Number: 510-332-4783
- Email: Gcpchan@aol.com
Study Locations
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Recruiting
- Bellevue Dermatology
-
Contact:
- Clive M Liu, MD
- Phone Number: 425-455-2275
- Email: Cliveliumd@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
- Male or Female and is at least 18 years of age, at the time of enrollment.
Females of childbearing potential (FCBP)† must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive§ options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; 3. OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on investigational product and for at least 28 days after the last dose of investigational product.
- † A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) consecutive months (that is, has had menses at any time during the preceding 24 consecutive months).
- § The female subject's chosen form of contraception must be effective by the time the female subject is randomized into the study (for example, hormonal contraception should be initiated at least 28 days before randomization).
- Patients with an established diagnosis of FFA based on the enrolling investigator's clinical judgment
Patients who have been treated and failed one standard therapy including
- Topical steroids
- Short course systemic steroids
- Systemic antibiotics
- Patients who are on stable dose of topical steroids or systemic antibiotics
- Patient and/or legal guardian has voluntarily signed and dated an informed consent/patient authorization form approved by an Institutional Review Board (IRB)/Ethics Committee (EC) if applicable according to local law, after the nature of the study has been explained and the patient has had the opportunity to ask questions.
Exclusion Criteria:
- Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
- Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
- Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
- Pregnant or breast feeding.
- Active substance abuse or a history of substance abuse within 6 months prior to Screening.
- Malignancy or history of malignancy, except for: a. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas; b. treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.
- Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
- Prior treatment with apremilast.
- Patient who have underlying chronic infections including HIV, Hep B and C.
- History of uncontrolled depression.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm with apremilast
Open label arm treating frontal fibrosing alopecia with apremilast
|
Open label treatment with apremilast
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lichen Planopilaris index
Time Frame: Week 0 to 24, patient visit week0,2,4,8,12,16,20,24
|
The weights given to the symptoms (30%), signs (30%), anagen pull test (25%), and presence of spreading (15%) led to the equation: LPPAI (0-10) = (pruritus + pain + burning)/3 + (scalp erythema + perifollicular erythema + perifollicular scale)/3 + 2.5 (pull test) + 1.5 (spreading/2). Symptoms and signs are recorded on a 4-point scale. The anagen pull test involves grasping a small group of 10 to 20 hairs between the thumb, second finger, and third finger at the scalp end of the hair shafts, and pulling away from the scalp with a slow, firm perpendicular force to slide the fingers to the ends of the hair. The result is recorded both as a binary value (0 for no anagen hairs and 1 for the presence of anagen hairs) and as anagen hairs/total hairs pulled. Last is the assessment of spreading, recorded as 0 (no spreading) versus 1 (indeterminate) versus 2 (spreading). Our primary endpoint is percentage change from baseline |
Week 0 to 24, patient visit week0,2,4,8,12,16,20,24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physicians global assessment
Time Frame: Weeks 0 to 24, patient visit week 0,2,4,8,12,16,20,24
|
Physicians global assessment This is a a five point scale used to measure the severity of the disease at the time of the physicians evaluation.
0-Clear, 1-Almost Clear, 2-Mild, 3-Moderate, 4-Severe The lower the score the better the score
|
Weeks 0 to 24, patient visit week 0,2,4,8,12,16,20,24
|
Visual Analogue Scale Pruritus
Time Frame: Weeks 0 to 24, patient visit week 0,2,4,8,12,16,20,24
|
Patient draws a line that best represent the severity of itch: this is continuous scale from 0-10, 0 being no itching and 10 being worst possible itching.
Patient is to draw a line along the scale that represent the itch.
|
Weeks 0 to 24, patient visit week 0,2,4,8,12,16,20,24
|
Frontal Fibrosing Alopecia Index
Time Frame: Weeks 0 to 24, patient visit weeks 0,2,4,8,12,16,20,24
|
This is a scoring system recently proposed by Holmes et al from the British Nail and Hair society.
FFASI was compiled in two forms: FFASI and FFASI B. FFASI utilizes clinical images of the entire hairline, divided into four sections.
Alopecia severity is graded 1-5 based on hairline recession.
In order that hairline recession comprises the greatest proportion of the assessment, each grade is weighted.
Nonscalp hair loss (eyebrow, eyelash, limb and flexural) are scored, as are associated features (facial papules; cutaneous, nail and mucosal lichen planus;and generalized scalp lichen planopilaris).
Scores for hairline recession, inflammatory band, nonscalp loss and associated features may be combined to give a maximum score of 100.
FFASI B uses the same format, but rather than grading alopecia it permits user-defined measurement of each hairline section.
We will look at mean change in FFASI compared to baseline
|
Weeks 0 to 24, patient visit weeks 0,2,4,8,12,16,20,24
|
Dermatology Quality of Life (DLQI) (Appendix E) Dermatology Quality of Life (DLQI) (Appendix E) Dermatology Quality of Life (DLQI)
Time Frame: Weeks 0 to 24, patient visit weeks 0,2,4,8,12,16,20,24
|
This is a questionnaire which measures how much a subjects skin problems affect his life over the last week.
It is a series of 10 questions regarding various daily activities and each question consist of 4 responses from Very much, A lot, A little to Not at all.
0-being not at all or not relevant , 1-a little, 2-a lot, 3-very much in addition question 7, 3-prevent work or studying, the scores are added together for total score.
Interpretation of score: 0-1 No affect on patient's life, 2-4 small affect on patient's life, 6-10 moderate affect on patient's life, 11-20 large on affect on patien's life, 21-30 extreme affect on patient's life
|
Weeks 0 to 24, patient visit weeks 0,2,4,8,12,16,20,24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Clive Liu, MD, Bellevue Dermatology
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Pathological Conditions, Anatomical
- Hypotrichosis
- Hair Diseases
- Alopecia
- Alopecia Areata
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 4 Inhibitors
- Apremilast
Other Study ID Numbers
- BD1-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontal Fibrosing Alopecia
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Rubina AlvesUniversitat Internacional de CatalunyaUnknownFrontal Fibrosing AlopeciaSpain
-
University of MinnesotaNot yet recruiting
-
University of Alabama at BirminghamEli Lilly and CompanyNot yet recruitingFrontal Fibrosing AlopeciaUnited States
-
LEO PharmaCompletedFrontal Fibrosing AlopeciaUnited States
-
Institute of Dermatology, ThailandEnrolling by invitationFrontal Fibrosing Alopecia | Lichen PlanopilarisThailand
-
Washington University School of MedicineCompletedFrontal Fibrosing Alopecia | Lichen PlanopilarisUnited States
-
University Hospital, BrestTerminatedAlopecia | Lichen PlanusFrance
-
University of MinnesotaCompletedFrontal Fibrosing Alopecia | Central Centrifugal Cicatricial Alopecia | Scarring Alopecia | Central Centrifugal Scarring Alopecia | Lichen PlanopilarisUnited States
-
Massachusetts General HospitalActive, not recruitingFrontal Fibrosing Alopecia | Lichen Planopilaris | Lichen Planopilaris of Scalp | Lichen Plano-PilarisUnited States
Clinical Trials on Apremilast
-
AmgenCompletedHealthy VolunteersUnited States
-
AmgenCompletedPsoriasis | Plaque-type PsoriasisUnited States, Canada
-
Diamant ThaciWithdrawnModerate to Severe Plaque PsoriasisGermany
-
University Hospitals Cleveland Medical CenterWithdrawn
-
AmgenCompletedPsoriatic ArthritisUnited States, Italy, Belgium, France, Canada, Taiwan, United Kingdom, Czechia, Russian Federation, Hungary, Germany, Bulgaria, Estonia, South Africa, Poland, Spain
-
AmgenCompletedPsoriatic ArthritisSpain, Canada, United States, Australia, Hungary, Poland, Austria, France, New Zealand, South Africa, Russian Federation, Germany, United Kingdom
-
Postgraduate Institute of Medical Education and...CompletedErythema Nodosum LeprosumIndia
-
Aga Khan UniversityWorld Health OrganizationCompletedPoliomyelitisPakistan
-
Jinnah Postgraduate Medical CentreCompleted
-
AmgenCompleted